KPTI (Karyopharm Therapeutics) Inventory Turnover: 0.35 (As of Mar. 2026)

What is Karyopharm Therapeutics Inventory Turnover?

Karyopharm Therapeutics KPTI +6.27% 52 Inventory Turnover is 0.35 as of Mar. 2026. GuruFocus rates KPTI with a GF Score™ of 52/100 and a GF Value™ of $6.28 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Karyopharm Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2026 was $1.3 Mil. Karyopharm Therapeutics's Average Total Inventories for the quarter that ended in Mar. 2026 was $3.8 Mil. Karyopharm Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.35.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Karyopharm Therapeutics's Days Inventory for the three months ended in Mar. 2026 was 259.06.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Karyopharm Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.11.

Karyopharm Therapeutics (NAS:KPTI) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Karyopharm Therapeutics's Days Inventory for the three months ended in Mar. 2026 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2026 )	/	Cost of Goods Sold (Q: Mar. 2026 )	*	Days in Period
	=	3.8185	/	1.345	*	365 / 4
	=	259.06

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Karyopharm Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	3.8185	/	35.066
	=	0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Karyopharm Therapeutics Inventory Turnover Related Terms

Karyopharm Therapeutics Inventory Turnover Historical Data

* Premium members only.

The historical data trend for Karyopharm Therapeutics's Inventory Turnover can be seen below:

Karyopharm Therapeutics Inventory Turnover Chart

Karyopharm Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Inventory Turnover

Get a 7-Day Free Trial

1.01

1.25

1.36

1.54

1.36

Karyopharm Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Inventory Turnover	Get a 7-Day Free Trial															0.27	0.22	0.47	0.37	0.35

52GF Score

Karyopharm Therapeutics Inc KPTI

Inventory Turnover is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Karyopharm Therapeutics Inventory Turnover Calculation

Karyopharm Therapeutics's Inventory Turnover for the fiscal year that ended in Dec. 2025 is calculated as

	Inventory Turnover (A: Dec. 2025 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (A: Dec. 2025 )	/ (	(Total Inventories (A: Dec. 2024 )	+	Total Inventories (A: Dec. 2025 ))	/	count )
=	5.949	/ (	(4.739	+	4.038)	/	2 )
=	5.949	/	4.3885
=	1.36

Karyopharm Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

	Inventory Turnover (Q: Mar. 2026 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (Q: Mar. 2026 )	/ (	(Total Inventories (Q: Dec. 2025 )	+	Total Inventories (Q: Mar. 2026 ))	/	count )
=	1.345	/ (	(4.038	+	3.599)	/	2 )
=	1.345	/	3.8185
=	0.35

Frequently Asked Questions Learn more about Inventory Turnover →

What does a Inventory Turnover of 0.35 mean?

Karyopharm Therapeutics (KPTI) has a Inventory Turnover of 0.35 as of Mar. 2026. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Karyopharm Therapeutics and its competitors.

Is Karyopharm Therapeutics' Inventory Turnover too high?

Karyopharm Therapeutics' current Inventory Turnover is 0.35. Overall, Karyopharm Therapeutics has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Karyopharm Therapeutics' Inventory Turnover compare to CHRS and TARA?

Karyopharm Therapeutics' Inventory Turnover of 0.35 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Inventory Turnover for a Biotechnology company?

A good Inventory Turnover depends on the Biotechnology industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Inventory Turnover mean?

A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Karyopharm Therapeutics and its competitors. Karyopharm Therapeutics's current Inventory Turnover is 0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Karyopharm Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Karyopharm Therapeutics (KPTI) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.28, compared to a current price of $10.67 — trading 69.9% above its estimated fair value. The current Inventory Turnover is 0.35. Karyopharm Therapeutics' overall GF Score™ is 52/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Inventory Turnover calculated?

Inventory Turnover is calculated from a company's financial statements. For Karyopharm Therapeutics (KPTI), the current Inventory Turnover is 0.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Karyopharm Therapeutics (KPTI) Overvalued in 2026?

Based on GuruFocus' analysis, Karyopharm Therapeutics stock appears to be overvalued. The current stock price of $10.67 is trading 69.9% above its estimated GF Value™ of $6.28. GuruFocus considers Karyopharm Therapeutics to be Significantly Overvalued.

Key valuation signals for KPTI:

Inventory Turnover: 0.35
GF Value™: $6.28 vs. price of $10.67 (69.9% above fair value)
GF Score™: 52/100 with 8 warning signs

No single metric tells the full story. See the KPTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Karyopharm Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies CHRS TARA CNTN RNA AVXL QTTB SLGL FATE CAMP CDXS VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges 25K0:Germany

Address 85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459

Website https://www.karyopharm.com

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).

52GF Score

Get the complete analysis for KPTI

Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.67

Price

$6.28

GF Value

View KPTI Analysis

See Inventory Turnover data for all stocks →